FHIT
FHIT (fragile histidine triad diadenosine triphosphatase, also known as FRA3B or AP3Aase) is a bis(5'-adenosyl)-triphosphatase of the histidine triad superfamily. It hydrolyses diadenosine polyphosphates, takes part in purine metabolism and functions as a tumour suppressor. Browse Assay Genie's current range of FHIT research reagents below, or read on for the biology behind the target.
FHIT is a dinucleoside triphosphate hydrolase. It cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A) to give AMP and ADP, and can also hydrolyse P(1)-P(4)-bis(5'-adenosyl) tetraphosphate (Ap4A), although its activity towards ATP is extremely low. The enzyme additionally shows adenylylsulfatase activity, releasing AMP and sulfate from adenosine 5'-phosphosulfate, and adenosine 5'-monophosphoramidase activity, converting purine nucleotide phosphoramidates such as AMP-NH2 to AMP. It can also catalyse ammonolysis reactions, including formation of adenosine 5'-phosphoramidate from adenosine 5'-phosphosulfate.
Beyond catalysis, FHIT modulates transcriptional activation by CTNNB1 and so helps regulate genes needed for cell proliferation and survival, such as CCND1 and BIRC5. It contributes to apoptosis through SRC and AKT1 signalling, and it inhibits MDM2-mediated proteasomal degradation of p53/TP53, supporting p53-mediated apoptosis. Induction of apoptosis depends on the ability of FHIT to bind Ap3A or related compounds, but not on its catalytic activity. Part of this effect may come from the mitochondrial form, which sensitises low-affinity Ca(2+) transporters and enhances mitochondrial calcium uptake. The protein is found in the cytoplasm, mitochondrion and nucleus.
The FHIT gene spans the common fragile site FRA3B, which gives the gene its former names, fragile histidine triad gene and FRA3B. Carcinogen-induced damage at this site can lead to translocations and aberrant transcripts, and such transcripts have been found in about half of all oesophageal, stomach and colon carcinomas. Loss of FHIT activity results in replication stress and DNA damage. HGNC places the gene in the histidine triad superfamily and in the group of microRNA protein coding host genes. Mouse and rat orthologs are both named Fhit.
FHIT functions as a tumour suppressor, and aberrant transcripts from the gene occur in oesophageal, stomach and colon carcinomas.
The gene lies within fragile site FRA3B, and loss of FHIT activity causes replication stress and DNA damage.
FHIT inhibits MDM2-mediated degradation of p53 and acts through SRC and AKT1 pathways to promote apoptosis.
FHIT hydrolyses Ap3A and Ap4A and acts on adenosine phosphosulfate and phosphoramidates, making it a model for diadenosine polyphosphate metabolism.
FHIT hydrolyses diadenosine triphosphate (Ap3A) to AMP and ADP and is involved in purine metabolism. It also modulates CTNNB1-driven transcription, inhibits MDM2-mediated degradation of p53 and promotes apoptosis. It functions as a tumour suppressor.
FHIT stands for fragile histidine triad diadenosine triphosphatase. Aliases include FRA3B and AP3Aase, and earlier names were fragile histidine triad gene and fragile histidine triad. UniProt names the protein bis(5'-adenosyl)-triphosphatase, EC 3.6.1.29.
The FHIT gene covers the common fragile site FRA3B, where damage can cause translocations and aberrant transcripts found in oesophageal, stomach and colon carcinomas. Orthologs exist in mouse and rat, both named Fhit; check the datasheet of any product for its validated reactivity.
Pathway partners and tumour suppressor proteins linked to FHIT biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P49789; product specifications from Assay Genie datasheets.